Skip to main content

OPKO Health, Inc. (OPK)

NASDAQ: OPK · IEX Real-Time Price · USD
3.67
-0.02 (-0.54%)
After-hours:Oct 22, 2021 7:59 PM EDT
3.69
-0.01 (-0.27%)
At close: Oct 22, 4:00 PM
Market Cap2.51B
Revenue (ttm)1.91B
Net Income (ttm)70.91M
Shares Out647.00M
EPS (ttm)0.11
PE Ratio33.55
Forward PE74.07
Dividendn/a
Ex-Dividend Daten/a
Volume1,809,451
Open3.66
Previous Close3.70
Day's Range3.63 - 3.70
52-Week Range3.02 - 6.27
Beta1.75
AnalystsBuy
Price Target6.60 (+78.9%)
Est. Earnings DateOct 28, 2021

About OPK

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers ...

IndustryBiotechnology
IPO DateNov 2, 1995
CEOPhillip Frost
Employees5,269
Stock ExchangeNASDAQ
Ticker SymbolOPK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for OPKO Health stock is "Buy." The 12-month stock price forecast is 6.60, which is an increase of 78.86% from the latest price.

Price Target
$6.60
(78.86% upside)
Analyst Consensus: Buy

News

Should you buy OPKO Health shares? Analysts remain bullish despite the pullback

On Monday, Opko Health Inc. (NASDAQ:OPK) shares edged slightly higher after Jefferies and Piper Sandler analysts issued upbeat statements following Friday's decline. The OPK stock price slipped more tha...

3 weeks ago - Invezz

OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed

The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.

3 weeks ago - Zacks Investment Research

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Gr...

NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review...

4 weeks ago - GlobeNewsWire

GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes

GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today ann...

1 month ago - PRNewsWire

OPKO Health (OPK) Forms JV, Establishes Presence in China

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

1 month ago - Zacks Investment Research

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in ...

SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversif...

1 month ago - GlobeNewsWire

Best Reddit Penny Stocks To Buy Now? 5 For Your List In September 2021

Which Reddit penny stocks are on your watchlist right now? The post Best Reddit Penny Stocks To Buy Now?

Other symbols:BDSICYRNIDEXSONM
1 month ago - PennyStocks

OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpati...

MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19. The U.S....

1 month ago - GlobeNewsWire

OPKO Health to Participate in Two Upcoming Investment Conferences

MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences.

1 month ago - GlobeNewsWire

Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New Yor...

CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), anno...

Other symbols:RAD
1 month ago - Business Wire

OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout

OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.

2 months ago - Zacks Investment Research

BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal...

2 months ago - PRNewsWire

Top Penny Stocks to Buy? Why These 3 Should Be on Your Watchlist

Are these penny stocks worth watching with the stock market down today? The post Top Penny Stocks to Buy?

Other symbols:ATIPWHLM
2 months ago - PennyStocks

3 Hot Biotech Penny Stocks to Watch With High Volume in 2021

Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...

Other symbols:AKBASEEL
2 months ago - PennyStocks

Why Opko Health Shares Shriveled by Nearly 8% on Friday

The coronavirus stock didn't impress with its Q2 results.

2 months ago - The Motley Fool

OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down

OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.

2 months ago - Zacks Investment Research

OPKO Health (OPK) Reports Q2 Loss, Misses Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of -250.00% and -3.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

2 months ago - GlobeNewsWire

Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to Decline

OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021

MIAMI, July 20, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, ...

3 months ago - GlobeNewsWire

7 Reddit Penny Stocks About to Explode

With Reddit's regular targets finally dropping, these stocks could be the next target for another crazy wave of Reddit Penny Stocks. The post 7 Reddit Penny Stocks About to Explode appeared first on Inv...

Other symbols:AMRNGOEDIAGOMQSRIGWIT
3 months ago - InvestorPlace

Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week

The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.

Other symbols:BNGONVTA
3 months ago - The Motley Fool

OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology

OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.

3 months ago - Zacks Investment Research

OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy

OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizi...

3 months ago - Benzinga

OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics

MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) f...

3 months ago - GlobeNewsWire